Adial Pharmaceuticals, Inc. Prepaid Expense and Other Assets, Current
Adial Pharmaceuticals, Inc. (ADIL) had Prepaid Expense and Other Assets, Current of $133.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-14
- 2026-06-30: Prepaid Expense and Other Assets, Current $133.00K.
- 2026-03-31: Prepaid Expense and Other Assets, Current $218.85K.
- 2025-12-31: Prepaid Expense and Other Assets, Current $300.00K; Prepaid Expense and Other Assets, Current as first filed $299.67K.
- 2025-09-30: Prepaid Expense and Other Assets, Current $407.54K.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $133.00K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $218.85K 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $300.00K 10-Q · filed 2026-08-14 | $299.67K 10-K · filed 2026-03-05 |
| 2025-09-30 | $407.54K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $163.65K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $263.39K 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $308.24K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $409.81K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $188.60K 10-Q · filed 2024-08-13 | |
| 2023-12-31 | $371.60K 10-K · filed 2025-03-04 | |
| 2023-09-30 | $469.61K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $91.37K 10-Q/A · filed 2023-10-30 | |
| 2023-03-31 | $223.36K 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $349.44K 10-K · filed 2024-04-01 | |
| 2022-09-30 | $504.10K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $194.05K 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $265.90K 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $389.50K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $569.78K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $147.07K 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $297.51K 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $501.69K 10-K · filed 2022-03-28 | |
| 2020-09-30 | $592.83K 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $176.76K 10-Q · filed 2020-08-13 | |
| 2020-03-31 | $240.38K 10-Q · filed 2020-05-14 | |
| 2019-12-31 | $359.50K 10-K · filed 2021-03-22 | |
| 2019-09-30 | $510.88K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $155.21K 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $279.42K 10-Q · filed 2019-05-13 | |
| 2018-12-31 | $317.55K 10-K · filed 2020-03-20 | |
| 2018-09-30 | $428.59K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $30.04K 10-Q · filed 2018-09-10 | |
| 2017-12-31 | $9.00K 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |